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It is now accepted that metabolic disor-
ders such as type 2 diabetes (T2D) and
obesity are characterized by alterations in
immune cells. Indeed, immune cells have
been shown to play a critical role in fuel-
ing the inflammation that accompanies
increased fat deposition and insulin resis-
tance. Both the innate (macrophages) and
the adaptive arm (CD4 and CD8 T cells,
in particular) significantly contribute to
the chronic inflammatory state that char-
acterizes these conditions. B cells, how-
ever, have until recently remained signif-
icantly understudied. This is not due to
the fact that they do not play as signif-
icant a role, as more recent publications
appear to show. Here, we briefly review
the most recent literature and highlight the
remaining outstanding questions.
A CROSS TALK BETWEEN B CELLS AND
ADIPOCYTES?
B lymphocytes or B cells are the arm of
the adaptive immune system responsible
for the generation of antibodies. In addi-
tion, they produce cytokines that support
the activation of other immune cells (1).
Whether they interact and influence the
physiology or pathophysiology of other
non-immune cells, such as adipocytes in
obesity, is only now beginning to emerge.
Adipocytes themselves secrete cytokines
also secreted by immune cells, such as
TNFα, IL-6, and IL-8 (2). However,
adipocytes secrete cytokines at significantly
lower levels than the immune cells infiltrat-
ing adipose tissue in obesity (2). Adipocytes
also secrete adipocyte-specific cytokines
known as adipokines, these include lep-
tin, adiponectin, resistin, which are also
altered in obesity (3). The receptors for
both leptin and adiponectin have been
found on B cells; however, their role is still
not understood. There is some evidence
that leptin induces secretion of IL-10, IL-6,
and TNFα in human B cells (4). However,
how adipokines affect B cells and whether
this plays a role in obesity has not been
sufficiently addressed yet.
B CELLS IN OBESE ADIPOSE TISSUE
AND T2D: SIMILARITIES AND
DIFFERENCES BETWEEN MOUSE AND
MAN
Recently, a number of studies have revealed
B cells contribute to the progression and
severity of obesity and T2D.
During weight gain, the earliest infiltra-
tors into adipose tissue are IFNγ-secreting
CD8+ T cells, then followed by M1-
polarized, inflammatory macrophages,
which secrete IL-6, IL-12, and TNFα (5).
Conversely, anti-inflammatory mediators
such as CD4+ T regulatory cells and
M2-polarized macrophages are reduced in
obese adipose tissue (6). The activation
of pro-inflammatory immune cells during
obesity is likely caused by the release of
free fatty acids (FFAs), high-glucose levels,
reactive oxidative species, and hypoxia (7).
Once established, this inflammatory envi-
ronment is thought to contribute to the
development of metabolic disease symp-
toms, such as insulin resistance, caused by
a disruption in normal metabolic signaling
pathways.
In the adipose tissue of obese humans,
B cells, together with IgG and IgM depo-
sition, have been observed in crown-like
structures (8), areas defined by accu-
mulation of macrophages around dying
adipocyte cells (9). Similarly, in wild-type
mice, B cells are rarely observed within lean
adipose tissue but begin to infiltrate after
4 weeks of mice being fed a high-fat diet
(HFD) (10). Mice lacking both B and T
cells do not show any differences in weight
gain or induction of glucose intolerance
on a HFD. Interestingly, however, obese
adipose tissue has a greater macrophage
infiltration in the absence of B and T cells,
suggesting that lymphocytes may influence
the recruitment of macrophages in obesity
(10).
In humans, T2D is strongly linked to
obesity (11), and many murine models of
obesity have been used to study induc-
tion of T2D symptoms (12). Cytokine
production by B cells is altered in both
T2D patients and obese mice. In T2D
patients, B cells constitutively secrete the
pro-inflammatory chemoattractant IL-8,
while also secreting lower levels of IL-10,
TNFα, and IL-6 than non-diabetic con-
trols (13). Similarly, LPS-stimulated B cells
from obese mice secrete higher amounts of
macrophage inflammatory protein-2 alpha
(MIP-2), the murine ortholog of human
IL-8, as well as lower levels of IL-10 (14).
Thus, the pro-inflammatory phenotype
seen in human T2D patients is recapit-
ulated in obese mice. Not all cytokines
behave in the same way, though, secretion
of IL-6 and TNFα is increased in murine
B cells from obese mice (14), yet decreased
in human T2D patients (13). These differ-
ences might be species-specific or highlight
the limitations of using obese murine mod-
els to model T2D. Overall, murine B cells
will have a more pronounced inflamma-
tory phenotype compared to the human
counterpart in T2D.
LESSONS FROM B CELL-DEFICIENT
MICE
In order to define whether B cells are
critical players in obesity and metabolic
disease, different research groups used B
cell-deficient mice, such as the µMT line,
in which disruption of the B cell recep-
tor µ chain, required for differentiation
and survival of mature B cells, results in
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loss of B cells (15). Overall, µMT mice
on a HFD developed obesity similarly to
wild-type mice. Crucially, however, they
did not present the glucose intolerance nor-
mally induced by HFD (14, 16). µMT mice
had resting serum glucose and insulin lev-
els closer to that of lean mice, as well as
improved glucose and insulin tolerance test
responses. This implies a strong role for B
cells in promoting the development of T2D
during obesity; nonetheless, the mecha-
nism by which B cell exert this effect is still
controversial.
One proposed mechanism is that B
cells influence the development of T2D
by promoting a pro-inflammatory pheno-
type in macrophages and T cells. µMT
mice had fewer macrophages within the
adipose tissue and increased expression
of anti-inflammatory M2 markers, such
as Arg 1 and Ym1 (14). Furthermore, B
cell-deficient mice showed reduced serum
levels of inflammatory cytokines such
as TNFα, IL-6, and MCP-1, as well as
reduced mRNA expression of IFNγ and
CD8 within the adipose tissue (14). Thus,
B cells appear to be involved in induc-
ing a pro-inflammatory phenotype in both
macrophages and T cells during obesity.
Interestingly, µMT mouse adipocytes also
secreted less leptin; however, the authors
did not investigate if this is a direct or
indirect effect of B cells (14).
How exactly B cells influence macro-
phages and T cells has been in part
addressed by another study, which also
highlighted the importance of antibody
secretion by B cells. Winer et al. (16)
observed IgG antibodies within adipose tis-
sue of obese mice and B cell infiltration of
visceral adipose tissue (VAT) early in obe-
sity development (16). Furthermore, the
proportion of B cells within VAT that were
class-switched (IgG+) increased over time
when mice were fed a HFD. Splenic B cells
from obese mice secreted more IgG and
less IgM, which suggests that B cells are
activated and switch to a memory pheno-
type during obesity. In the serum and adi-
pose tissue, the IgG2c subclass, in particu-
lar, was significantly increased. Deposits of
IgM and IgG were also reported in crown-
like structures within VAT (16), similar to
that observed in human (8). Winer et al.
(16) proposed the obesity-induced anti-
body response to be pathogenic and to
directly contribute to development of T2D
via macrophages. Macrophages express Fc
receptors that bind antibodies, the bind-
ing of which can be activating or inhibitory
depending on the class of Fc receptor (17).
Within the adipose tissue, µMT mice had
fewer infiltrating M1-macrophages (16).
Injection of purified IgG antibodies from
obese mice inµMT mice increased the M1-
macrophage infiltrate into VAT, as well as
increasing macrophage TNFα secretion in
culture (16). Most importantly, the symp-
toms of T2D were worsened in obese mice
injected with purified IgG from obese mice,
but not with IgG from lean mice (16).
This strongly suggests the presence of path-
ogenic autoantibodies. How exactly the
pathogenic IgG affects the phenotype of
macrophages remains to be elucidated. It
is important to note, however, that two
additional publications reported lack of
pathogenic IgGs (14) and no evidence
of IgG secretion or class-switching of B
cells (18), indicating that the involvement
of antibodies in obesity may be model-
dependent. Further studies with additional
models are required to clarify this impor-
tant point.
On a different level, Winer at al. (16)
also observed less IFNγ+ CD8+ cells
within obese adipose tissue in µMT.
They proposed that, as well as influ-
encing macrophages via immunoglobulin
secretion; B cells also prime both CD4+
and CD8+ T cells via MHCI/II interac-
tion. By specifically removing MHCI or
MHCII from B cells, glucose tolerance and
insulin sensitivity improved TNFα levels
within the adipose tissue decreased and
IFNγ secretion by CD8+ cells was down
regulated (16). Importantly, the authors
were then able to lessen the symptoms
of obesity-dependent insulin resistance by
depleting B cells with an anti-CD20 anti-
body. Although the depletion of B cells
did not affect weight, the levels of IgM
and IgG in the blood as well as the levels
of TNFα and TNFα+ macrophages were
reduced. As the depletion occurred after
obesity was established, it suggests that B
cells are required for both inducing and also
maintaining the pro-inflammatory pheno-
type in macrophages and T cells that con-
tributes to insulin resistance. It also indi-
cates that targeting B cells therapeutically
could improve the management of T2D.
B CELLS ARE ALSO INVOLVED IN
ADIPOSE TISSUE HOMEOSTASIS
In contrast to the pro-inflammatory role
of B cells in promoting metabolic disease
reported by others, Nishimura et al. (18)
provided evidence of a protective role for
a subset of B cells, regulatory B cells, also
known as B10 or IL-10-producing B cells.
IL-10 is an immunosuppressive cytokine
strongly associated with reducing autoim-
mune disease and inflammation (19). Reg-
ulatory B cells or Bregs are a subset of
B cells, which secrete IL-10 and TGF-β
(19), mediating suppressive effects on other
immune cells. In their research, Nishimura
et al. (18) showed that murine B cells iso-
lated from adipose tissue produce high
levels of IL-10, even in the absence of
any in vitro stimulation. In contrast, B
cells isolated from the spleen and lymph
nodes required stimulation in order to have
detectable levels of IL-10.
To prove the hypothesis that Bregs influ-
ence adipose inflammation, B cell specific
IL-10 knockout (KO) mice were estab-
lished using bone marrow chimeras. To do
this bone marrow cells comprising 10%
IL-10 KO cells and 90% B cell KO cells
were transferred into wild-type mice, such
that all resulting B cells were IL-10 defi-
cient (18). The infiltration of macrophages
in adipose tissue increased, as well as the
expression of pro-inflammatory markers
such as CD44 and IFNγ (18). From these
findings, it seems that there is a popula-
tion of regulatory B cells within the adi-
pose tissue that maintains homeostasis by
suppressing pro-inflammatory responses,
thus the production of IL-10 by B cells
is important in counterbalancing insulin
resistance.
The authors hypothesized that resident
B cells within adipose tissue are dependent
on local factors secreted by adipocytes, such
as FFAs. Indeed, FFA supported adipose B
cell survival and IL-10 production in cul-
ture (18). The binding of FFA to immune
cells has previously been suggested to be
via binding to toll-like receptor 4 (TLR4)
(20). However, if FFA secretion helps sup-
port Bregs within adipose tissue, it does
not explain their reduction in obesity. It
is possible that the secretion of additional
factors by obese adipocytes skew the Breg
phenotype; however, this is not addressed
in the paper.
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FIGURE 1 |The role of B cells in modulating inflammation in adipose
tissue. Lean adipose tissue contains resident Bregs, which constitutively
secrete IL-10 and suppress inflammation during homeostasis. However, in
obese adipose tissue the secretion of free fatty acids (FFA), hypoxia, high
glucose levels, reactive oxygen species (ROS), and necrosis activates
pro-inflammatory CD8+ cells and M1-polarized macrophages, generating
inflammation. B cells are also activated during obesity, although the
mechanism is still unclear. During obesity, B cells class-switch and secrete
pathogenic IgGs, as well as the macrophage-recruiting chemokine,
macrophage inflammatory protein-2 alpha (MIP-2). Furthermore, they also
activate T cells via MHCI/II interactions. Overall, it seems that the protective
role of Bregs is overcome by the pro-inflammatory role of activated B cells.
CONCLUDING REMARKS
The idea that Bregs counterbalance the pro-
inflammatory processes that characterize
adipose tissue in obesity does not necessar-
ily contrast with previous studies showing
that the complete absence of B cells amelio-
rates inflammation and insulin resistance
in obese mice. It is possible to specu-
late that Bregs are present in high num-
bers within the lean adipose tissue, possi-
bly to avoid the development of inflam-
mation in normal conditions. In support
of this view, it has been reported that in
humans IL-10 RNA levels in adipose tis-
sue are inversely correlated with body mass
index, whether this is due to Bregs or
not remains to be established (18). Once
homeostasis is lost, however, as observed
in the adipose tissue of mice on HFD, the
effect of activated B cells that prime T cells
and generate immunoglobulins that affect
macrophages, fueling the inflammatory
response, overwhelms the protective effect
of IL-10 producing Bregs (summarized in
Figure 1). Experiments to determine how
B cell subsets change during obesity pro-
gression and if individuals with lower levels
of Bregs are more prone to insulin resis-
tance would be required to further clarify
the role of Bregs in obesity. Nonetheless, the
observation that once obesity is established,
insulin resistance can be ameliorated by B
cell depletion via an anti-CD20 treatment
offers an interesting therapeutic opportu-
nity and warrants further investigation into
B cell function in obesity.
FURTHER QUESTIONS FOR B CELLS
AND METABOLISM
In order to have a better understanding of
how B cells affect all body-metabolism, it
will also be necessary to gain more infor-
mation on what metabolic pathways regu-
late B cells, their differentiation, cytokine
production, and antibody secretion.
Whereas glucose metabolism and the
pentose phosphate pathways are necessary
to support B cell clonal expansion (21), we
still know little about the differentiation to
antibody-secreting cells and cytokine pro-
duction. Fatty acid biosynthesis is up regu-
lated in antibody-secreting cells, in order to
sustain the expansion of the endoplasmic
reticulum to support antibody production
(22). But what effect will an increase in free
fatty acid uptake have on the B cell pheno-
type? Further research efforts are required
to get a more comprehensive picture, which
will ultimately help understanding the role
of B cells in metabolic disorders and how
to intervene therapeutically.
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